Evaluation of the Efficacy of Dissociation-Focused Cognitive Behavior Therapy: a Multicenter Randomized Controlled Trial
- Conditions
- Dissociative Disorder
- Registration Number
- NCT06917209
- Lead Sponsor
- University Hospital, Tours
- Brief Summary
Dissociative symptoms and disorders are particularly prevalent in the general population and among people suffering from psychiatric disorders. To date, no treatment has proven effective for this type of problem. Exploratory studies (without control group) have been carried out. Among these studies, dissociation-focused cognitive behavioral therapy (DF-CBT) seems promising. DF-CBT is based on a solid empirical model that has received numerous scientific evidence.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 140
- ≥ 18 years
- Membership of a social security scheme
- Participant's express consent
- Have at least one diagnosis of dissociative disorder among the following:
depersonalization/derealization disorder, dissociative identity disorder, unspecified dissociative disorder.
- Be able to carry out psychotherapy sessions.
- If taking psychiatric medication, treatment must have been stable for at least 30 days.
- Present one of the following current diagnoses: substance use disorder (excluding tobacco), neurodevelopmental disorder, anorexia nervosa, severe depressive disorder, schizophrenia spectrum disorder, bipolar disorder, personality disorder other than borderline personality disorder.
- Present cognitive deficits.
- Be engaged in psychotherapeutic work.
- Be undergoing benzodiazepine treatment.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Difference in Dissociative Experience Scale (DES) Between randomization and 3 months after Difference in Dissociative Experience Scale (DES) between randomization and 3 months after.
The DES assesses dissociation through 28 items. The total score ranges between 0 and 100, where high scores indicate high levels of dissociation.
- Secondary Outcome Measures
Name Time Method Hetero-administered visual analogue scale At randomization, 3 months and 6 months after Visual analogue scales in which the practitioner rates the intensity of the patient's dissociative symptoms on the basis of his/her clinical assessment.
Dissociative Experiences Scale (DES) At 6 months after randomization The DES assesses dissociation through 28 items. The total score ranges between 0 and 100, where high scores indicate high levels of dissociation.
Hospital Anxiety Depression Scale (HADS) Randomization, 3 months and 6 months after Hospital Anxiety Depression Scale (HADS) is a 14-item self-report questionnaire. Two sub-scores (anxiety and depression) are calculating.
Both scores range between 0 and 21 with 0 corresponding to the ideal score (no anxiety or depression symptoms).Dissociation Questionnaire (DIS-Q) At randomisation, 3 months and 6 months after The Dissociation Questionnaire is a 63-item questionnaire measuring dissociative-trait manifestations. Participants respond to each item using a 5-point Likert scale. Four sub-scores (loss of control, absorption, amnesia and identity confusion) are calculated.
Post traumatic stress disorder checklist scale (PCL-5) Randomization, 3 months and 6 months after The post traumatic stress disorder checklist scale (PLC-5) is 20-item scale to assess post-traumatic stress symptoms. Participants respond to each item using a 5-point Likert scale. The score ranges between 0 and 80, with 0 reflecting no post traumatic stress disorder.
Satisfaction With Life Scale (SWLS) Randomization, 3 months and 6 months after The Satisfaction With Life Scale (SWLS) is a 5-item questionnaire assessing quality of life. Participants respond to each item using a 7-point Likert scale. The score range bewteen 0 and 35 with 35 reflects an extreme satisfaction with life.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.